Article Text

Unexpected outcome (positive or negative) including adverse drug reactions
Acute pancreatitis during interferon-alpha and ribavirin treatment for hepatitis C
  1. Jane da Silva1,
  2. Simone Batisti Giroldi2,
  3. Franciani de Oliveira Basso3,
  4. Georgia Nunes Antunes4,
  5. Luis Augusto Borba4,
  6. Cássio Renato Montenegro de Lima1
  1. 1
    UNISUL - Universidade do Sul de Santa Catarina, Medicine, Av Pedra Branca, 25, Cidade Universitária Pedra Branca, Palhoça, 88132-000, Brazil
  2. 2
    Universidade do Extremo Sul Catarinense, Medicine, Av Universitária, 1105, Criciuma, Santa Catarina, 88806-000, Brazil
  3. 3
    Complexo Hospitalar Santa Casa de Porto Alegre, Rua: Prof. Annes Dias, 295, Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
  4. 4
    Hospital São José, Rua Cel. Pedro Benedet, 630, Cx.P. 63, Criciuma, Santa Catarina, 88801-250, Brazil
  1. Jane da Silva, janedasilva{at}matrix.com.br

Summary

A patient treated with interferon-alpha and ribavirin for hepatitis C, who developed acute pancreatitis, is presented here along with a literature review. A 45-year-old Caucasian man was admitted to the intensive care unit because of an acute pancreatitis. According to the adverse drug reaction probability scale, it is probable that pancreatitis was induced by treatment (interferon and ribavirin) for chronic hepatitis C (CHC) commenced 2 months ago. We performed a literature search of all available English-language articles published on MEDLINE between January 1966 and July 2008 using the key terms “acute pancreatitis”, “interferon” and “ribavirin”; only four papers were found with a total of 13 reported cases demonstrating acute pancreatitis developed during treatment for CHC. Looking out for the minimal clinical signs and symptoms of acute pancreatitis in patients with CHC using interferon and ribavirin can help to detect this relevant and rare adverse drug reaction early.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.